New weight loss drug candidate shows early promise in stomach study

NCT ID NCT07429032

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called AMG 133 (Maridebart cafraglutide) in 57 adults with overweight or obesity. The goal was to see how the drug affects stomach emptying, using acetaminophen as a marker. Participants received either the drug or a placebo, and researchers measured how quickly the stomach emptied. The study is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMG 133 (Maridebart cafraglutide)
What this could lead to: If successful, this could help develop a new weight management drug that slows stomach emptying, potentially aiding weight loss.
What could go wrong: This is a very early Phase 1 trial with only 57 people, focused on stomach emptying rather than weight loss itself. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.